Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1126 to 1140 of 1425 results for primary care

  1. Intermittent urinary catheters: catheter selection:- For patients performing intermittent self-catheterisation over the long term, what is the clinical and cost effectiveness of single-use non-coated versus single-use hydrophilic versus single-use gel reservoir versus reusable non-coated catheters with regard to the following outcomes: symptomatic urinary tract infections, urinary tract infection-associated bacteraemia, mortality, patient comfort and preference, quality of life, and clinical symptoms of urethral damage?

    spinal cord injuries and people over 16 who regularly self-catheterise. The primary outcome measures should be incidence of symptomatic...

    Research recommendation
    Published
    9 June 2015

  2. The epilepsies: The diagnosis and management of the epilepsies in adults and children in primary and secondary care (CG20)

    This guideline has been updated and replaced by NICE guideline CG137.

    Withdrawn guideline

  3. Chronic kidney disease: early identification and management of chronic kidney disease in adults in primary and secondary care (CG73)

    This guidance has been updated and replaced by NICE guideline CG182.

    Withdrawn guideline

  4. Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment (TA1036)

    Evidence-based recommendations on elacestrant (Korserdu) for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment in adults.

    Technology appraisal guidance
    Published
    5 February 2025
    View recommendations

    Sections for TA1036

  5. Postpartum haemorrhage: What is the most effective treatment for primary postpartum haemorrhage?

    Question Postpartum haemorrhage: What is the most effective treatment for primary postpartum haemorrhage? Any explanatory notes(if...

    Research recommendation
    Published
    6 January 2023

  6. Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease (TA223)

    Evidence-based recommendations on cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for treating intermittent claudication in adults with peripheral arterial disease.

    Technology appraisal guidance
    Published
    25 May 2011
    View recommendations

    Sections for TA223

  7. SecurAcath for securing percutaneous catheters (HTG440)

    Evidence-based recommendations on SecurAcath for securing percutaneous catheters.

    HealthTech guidance
    Last updated
    10 August 2022
    View recommendations

    Sections for HTG440

  8. Noctura 400 Sleep Mask for diabetic retinopathy and diabetic macular oedema (MIB144)

    NICE has developed a medtech innovation briefing (MIB) on Noctura 400 Sleep Mask for diabetic retinopathy and diabetic macular oedema .

    Medtech innovation briefing
    Published
    24 April 2018

  9. What is the effectiveness of high-pressure non-invasive positive pressure ventilation (NIPPV) compared with continuous positive airways pressure (CPAP) flow driver as the primary mode of ventilation?

    compared with continuous positive airways pressure (CPAP) flow driver as the primary mode of ventilation? Any explanatory notes(if...

    Research recommendation
    Published
    16 August 2019

  10. Ranibizumab for treating choroidal neovascularisation associated with pathological myopia (TA298)

    Evidence-based recommendations on ranibizumab (Lucentis) for treating choroidal neovascularisation associated with pathological myopia in adults.

    Technology appraisal guidance
    Last updated
    20 May 2024
    View recommendations

    Sections for TA298

  11. Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban (TA697)

    Evidence-based recommendations on andexanet alfa (Ondexxya) for reversing anticoagulation form apixaban or rivaroxaban in adults with life-threatening or uncontrolled bleeding.

    Technology appraisal guidance
    Last updated
    15 January 2025
    View recommendations

    Sections for TA697

  12. What are the components of a decision aid to support people referred for elective joint replacement in making decisions about their treatment (for example, the type of procedure, timing and implant choice)?

    replacement surgery understand their options and make decisions about their care. Evidence from studies of decision aids for joint...

    Research recommendation
    Published
    10 August 2020

  13. Menopause: identification and management (NG23)

    This guideline covers identifying and managing menopause, including in people with premature ovarian insufficiency. It aims to improve the consistency of support and information provided to people experiencing menopause.

    NICE guideline
    Last updated
    7 November 2024
    View recommendations

    Sections for NG23

  14. Pegunigalsidase alfa for treating Fabry disease (TA915)

    Evidence-based recommendations on pegunigalsidase alfa (Elfabrio) for Fabry disease (also known as alpha-galactosidase deficiency) in adults.

    Technology appraisal guidance
    Published
    4 October 2023
    View recommendations

    Sections for TA915

  15. Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA768)

    Evidence-based recommendations on upadacitinib (Rinvoq) for treating active psoriatic arthritis in adults.

    Technology appraisal guidance
    Published
    2 February 2022
    View recommendations

    Sections for TA768